Tumor News and Research

RSS

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Study: Some countries take more time for reimbursement decisions on new cancer drugs

Some European countries take more than twice as long as others to reach health technology assessment decisions to reimburse new cancer drugs following their approval by the European Medicines Agency.

19 Oct 2018

Breast Cancer as a Dynamic Disease

An interview with Dr. Andrew Ewald, discussing the influence of the myoepithelium on breast cancer growth and the importance of studying metastasis.

19 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.

19 Oct 2018

Researchers investigate why some cancers affect only young women

Among several forms of pancreatic cancer, one of them affects specifically women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known as "mucinous cyst", has strange similarities with another mucinous cancer, affecting the ovaries.

19 Oct 2018

The immune system also plays a key role in day-to-day function of healthy organs

The cells of the immune system sustain life by infiltrating infected and dmaged tissue and eliminating pathogenic microorganisms and cell debris.

19 Oct 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

New approach to understanding cancers will accelerate development of better treatments

A new innovation in cancer research will enable scientists to understand the complex causes of the disease with unprecedented speed and sophistication. This will accelerate the development of new and better treatments, and it will help researchers find ways around roadblocks that now stand in their path.

19 Oct 2018

Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation

A group of Massachusetts General Hospital investigators is proposing that targeting immune checkpoints - molecules that regulate the activity of the immune system - in immune cells called microglia could reduce the inflammatory aspects of important neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

17 Oct 2018

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack.

17 Oct 2018

UC researcher focuses on light-mediated therapies to target breast cancer

When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.

17 Oct 2018

Loss of tumor protein p53 helps cancer cells grow in hostile environment

Researchers have discovered a novel consequence of loss of the tumor protein p53 that promotes cancer development, according to new findings in eLife.

17 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Patients once thought incurable can benefit from high-dose radiation therapy

In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer.

17 Oct 2018

Training young researchers to work with data volumes arising in the health sector

Investigation, diagnosis, and treatment of diseases give rise to big data volumes. Their systematic analysis may produce new findings for the diagnosis and therapy of diseases, such as cancer.

17 Oct 2018

Tumor News and Research

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Study: Some countries take more time for reimbursement decisions on new cancer drugs

Breast Cancer as a Dynamic Disease

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers investigate why some cancers affect only young women

The immune system also plays a key role in day-to-day function of healthy organs

Study finds differences in side-effects experienced by male and female OG cancer patients

New approach to understanding cancers will accelerate development of better treatments

Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation

Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer

UC researcher focuses on light-mediated therapies to target breast cancer

Loss of tumor protein p53 helps cancer cells grow in hostile environment

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Patients once thought incurable can benefit from high-dose radiation therapy

Training young researchers to work with data volumes arising in the health sector

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News